Arcutis Biotherapeutics (ARQT) FDA Announcement summary

Introduction and purpose

• ZORYVE (roflumilast) cream 0.15% received FDA approval for mild to moderate atopic dermatitis in patients aged 6 and older, marking its third indication in under 24 months.

• The launch aims to address significant unmet needs in atopic dermatitis, a chronic, burdensome skin disease affecting both children and adults.

• The product is positioned as a steroid-free, once-daily topical with broad insurance coverage and a focus on patient adherence.

• Arcutis and Kowa Pharmaceuticals America announced a co-promotion agreement to expand ZORYVE's reach in the U.S. primary care and pediatric markets.

Details of approval or decision

• FDA approved ZORYVE Cream 0.15% for mild to moderate atopic dermatitis in adults and children ages 6 and older, expanding its label and addressable market by 1.4 million patients.

• ZORYVE is now indicated for three major inflammatory skin diseases, making it the first steroid-free topical with such a broad label.

• The label allows once-daily use with no limitations on treatment area, body surface area, or duration.

• Kowa will use its primary care sales force to promote ZORYVE cream and foam for all FDA-approved indications to primary care practitioners and pediatricians.

Impact on industry and stakeholders

• The approval triples the total addressable market to 4.4 million commercially covered patients treated by dermatology clinicians.

• A new co-promotion agreement with Kowa Pharmaceuticals will expand access to millions treated outside dermatology offices.

• Kowa's established relationships in primary care are anticipated to enhance patient access and support.

• Sustained revenue growth and operational leverage are expected with new indications and expanded prescriber base.

• Early PBM coverage and anticipated rapid downstream insurance coverage are expected to accelerate market uptake.